Skip to main content

Table 2 Baseline characteristics of patients who experienced or not clinical relapses during the study course

From: Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients

 

Relapse yes (n = 31)

Relapse no (n = 117)

Significance

Gender (♀); patients (%)

20 (64.51)

72 (61.53)

χ2 = 0.92, p = 0.761

Age (years); mean (SD)

30.45 (± 7.66)

38.02 (± 10.42)

t = − 3.77, p < 0.001

EDSS*; mean (SD)

1.32 (± 0.83)

1.55 (± 0.86)

t = − 1.34, p = 0.181

Enhancing lesions**; patients (%)

18/31 (58)

55/81 (67.9)

χ2 = 1.36, p = 0.243

Naïve Treg percentage*; mean (SD)

33 (± 14)

28.16 (± 11.09)

t = 2.03, p = 0.044

TregCM percentage*; mean (SD)

42.63 (± 13.12)

46.52 (± 8.17)

t = − 2.04, p = 0.043

TregEM percentage*; mean (SD)

23.39 (± 6.28)

25.06 (± 8.10)

t = 0.27, p = 0.290

Tr1 percentage*; mean (SD)

3.83 (± 1.22)

4.68 (± 2.13)

t =− 2.10, p = 0.037

  1. SD standard deviation, Treg regulatory T cells, TregCM Treg central memory, TregEM Treg effector memory
  2. p-value calculation was done using Chi squared (χ2) or two independent sample t-test for categorical or continuous variables, respectively
  3. * Data determined at the pre-therapy time point
  4. ** These data are available for a subgroup of patients only